Immunic’s (IMUX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Immunic (NASDAQ:IMUX) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Immunic’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.74) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.06) EPS.

Other equities analysts have also issued reports about the stock. William Blair initiated coverage on shares of Immunic in a research report on Tuesday, March 25th. They set an “outperform” rating on the stock. D. Boral Capital restated a “buy” rating and set a $17.00 price objective on shares of Immunic in a report on Thursday, April 10th. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Immunic presently has a consensus rating of “Buy” and an average target price of $13.20.

Immunic Price Performance

IMUX stock opened at $0.98 on Tuesday. Immunic has a 12 month low of $0.83 and a 12 month high of $2.11. The firm’s 50-day moving average is $1.08 and its 200 day moving average is $1.15. The company has a market capitalization of $88.35 million, a PE ratio of -0.80 and a beta of 1.91.

Institutional Trading of Immunic

A number of hedge funds have recently bought and sold shares of the stock. State Street Corp increased its holdings in shares of Immunic by 7.5% in the 3rd quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after acquiring an additional 11,642 shares during the period. 683 Capital Management LLC grew its stake in Immunic by 2.2% in the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock valued at $700,000 after purchasing an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC raised its holdings in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after purchasing an additional 22,200 shares in the last quarter. Focus Partners Wealth raised its holdings in Immunic by 1.1% in the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Immunic during the third quarter valued at about $50,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.